Dec 2014/ Jan 2015
In This Issue
Tips from CRCs
Quick Links


Looking back on the accomplishments of 2014, we would like to thank you, our data manager volunteers, for your participation in training development and helping us plan the data managers meeting at Tandem.


Over the last year there has been an increased use of eLearning modules in the Learning Management System. We received more feedback and questions from data managers which improve the content of this training newsletter, and the eLearning modules.


One emphasis for this year is to complete an 'Essential Series' which focuses on the first forms and primary CIBMTR information that a data manager needs to know.


Your ideas are always welcomed. If you would like to have more input in the development of training materials, please contact: Lori Colt 


We're grateful for all of your work to provide us with necessary research data.  Hope you have a splendid year. 


CIBMTR Training


 CIBMTR is a research collaboration between the NMDP/Be The Match and Medical College of Wisconsin.

Tips from CRCs to Data Managers
  • If you have an issue while working in FormsNet that you can't resolve, send a screenshot and detailed summary to your CRC for investigation and resolution of the issue.
  • Create a resource for your center's data management team that contains questions that your center has submitted to CIBMTR with our responses and updates.
  • Develop an on-going training program by inviting your transplant physician's, laboratory staff, nurses, etc., to share HCT updates on your center's treatments, diseases, preparative regimen protocols, comorbidities, etc. Identify areas on the CIBMTR forms that your physicians could highlight in their presentations that would improve the quality of the data that your center is submitting.

Question 1 - Consolidation Therapy:  

Pre-TED Form 2400 question 456 asks how many cycles of induction therapy were required to achieve CR. How do you answer when the patient had one induction cycle that was considered an induction failure but then the patient achieved remission on consolidation therapy?



In a case like above, report that it took two cycles of induction therapy to achieve a CR. The second phase of chemotherapy is known as consolidation therapy. 


Induction therapy is termed as the first or primary line of treatment with the goal of reducing the number of cancer cells and making the cancer vulnerable to additional treatment. Induction therapy can include a wide variety of treatment methods and the application and dosage are determined by weighing the factors involved in the patient's case.


Consolidation therapy is used when an ALL (or AML) patient has achieved a hematologic remission in response to induction therapy. The goal of consolidation therapy is to destroy any remaining leukemia cells and sustain remission. 


If a center chooses to use "consolidation" type therapy as its first therapy to achieve a CR, the "consolidation" therapy should be reported as induction therapy. If the patient achieved a CR after the 2nd line of therapy, the disease status should be reported as CR, not as a PIF. 


Question 2 - Immunosuppressive Agent:  

I am reporting on a recipient who is off all immunosuppression to treat GVHD, but continues to receive extracorporeal photopheresis (ECP). How do I answer question 199 on the Form 2200, "Is the recipient still taking immunosuppressive agents (including PUVA) to treat or prevent GVHD?"



While ECP has a selective immunomodulatory effect rather than a generalized immunosuppressive effect, it should still be reported as an immunosuppressive agent to treat or prevent GVHD. Report "yes" for question 199 as long as systemic therapy to treat or prevent GVHD continues; if the recipient is only receiving topical agents - such as corticosteroid skin creams and/or budesonide - question 199 should be answered "No."
Send general questions into  Answers may be in a future newsletter.

Thank you to the contributors for this month's newsletter.

CIBMTR Training